Hans‐Hellmut Neumayer

6.7k total citations · 2 hit papers
103 papers, 4.9k citations indexed

About

Hans‐Hellmut Neumayer is a scholar working on Transplantation, Surgery and Nephrology. According to data from OpenAlex, Hans‐Hellmut Neumayer has authored 103 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Transplantation, 29 papers in Surgery and 23 papers in Nephrology. Recurrent topics in Hans‐Hellmut Neumayer's work include Renal Transplantation Outcomes and Treatments (50 papers), Neurological Complications and Syndromes (16 papers) and Organ Transplantation Techniques and Outcomes (13 papers). Hans‐Hellmut Neumayer is often cited by papers focused on Renal Transplantation Outcomes and Treatments (50 papers), Neurological Complications and Syndromes (16 papers) and Organ Transplantation Techniques and Outcomes (13 papers). Hans‐Hellmut Neumayer collaborates with scholars based in Germany, Switzerland and United States. Hans‐Hellmut Neumayer's co-authors include Klemens Budde, Lutz Fritsche, Alan G. Jardine, Edward Cole, Hallvard Holdaas, Bart Maes, Bengt Fellström, Carola Grönhagen‐Riska, Johannes Waiser and Gudrun Nyberg and has published in prestigious journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

In The Last Decade

Hans‐Hellmut Neumayer

102 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

2003 660 citations Hallvard Holdaas, Bengt Fellström et al. The Lancet profile →
Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection

2005 638 citations Lutz Fritsche, Birgit Rudolph et al. profile →

Peers

Countries citing papers authored by Hans‐Hellmut Neumayer

Since Specialization

Citations

This map shows the geographic impact of Hans‐Hellmut Neumayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Hellmut Neumayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Hellmut Neumayer more than expected).

Fields of papers citing papers by Hans‐Hellmut Neumayer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans‐Hellmut Neumayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Hellmut Neumayer. The network helps show where Hans‐Hellmut Neumayer may publish in the future.

Co-authorship network of co-authors of Hans‐Hellmut Neumayer

This figure shows the co-authorship network connecting the top 25 collaborators of Hans‐Hellmut Neumayer. A scholar is included among the top collaborators of Hans‐Hellmut Neumayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans‐Hellmut Neumayer. Hans‐Hellmut Neumayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor–Mediated Podocyte β3-integrin Activation 2015 ·Transplantation ·Oliver Staeck, Torsten Slowinski, Ina Lieker, Kaiyin Wu, Birgit Rudolph, Danilo Schmidt, Susanne Brakemeier, Hans‐Hellmut Neumayer, Changli Wei, Jochen Reiser, Klemens Budde, Fabian Halleck, Dmytro Khadzhynov	30
2	Renal Allograft Loss Caused by Cardiorenal Syndrome 2015 ·Transplantation ·Johannes Waiser, Fabian Knebel, Birgit Rudolph, Kaiyin Wu, (unknown), Wasiem Sanad, Klemens Budde, Hans‐Hellmut Neumayer, Fabian Halleck	8
3	Weight gain in long-term survivors of kidney or liver transplantation—Another paradigm of sarcopenic obesity? 2012 ·Nutrition ·Tatjana Schütz, (unknown), (unknown), (unknown), G. Kreymann, Klemens Budde, Lutz Fritsche, Hans‐Hellmut Neumayer, Herbert Lochs, Mathias Plauth	65
4	Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies) 2011 ·Transplantation ·Yves Vanrenterghem, Barbara A. Bresnahan, Josep M. Campistol, Antoine Dürrbach, Josep M. Grinyó, Hans‐Hellmut Neumayer, Philippe Lang, Christian P. Larsen, Eduardo Mancilla-Urrea, José Medina‐Pestana, A. Jay Block, Tao Duan, (unknown), Sheila Gujrathi, Flavio Vincenti	134
5	Pretransplant cardiovascular evaluation and posttransplant cardiovascular risk 2010 ·Kidney International ·James B. Young, Hans‐Hellmut Neumayer, Robert D. Gordon	25
6	Inflammation in Renal Transplantation 2009 ·Clinical Journal of the American Society of Nephrology ·Sadollah Abedini, Ingar Holme, (unknown), Gisela Weihrauch, (unknown), Alan G. Jardine, Edward Cole, Bart Maes, Hans‐Hellmut Neumayer, Carola Grönhagen‐Riska, (unknown), Hallvard Holdaas	89
7	Improving allograft survival 2005 ·Nephrology Dialysis Transplantation ·Hallvard Holdaas, Bengt Fellström, Alan G. Jardine, Edward Cole, Gudrun Nyberg, Carola Grönhagen‐Riska, Bart Maes, Hans‐Hellmut Neumayer, Sören Madsen, (unknown), Terje Pedersen, Anders Olsson, Hendrica Belge, Philippe Gailly, (unknown), Johannes Loffing, Renaud Beauwens, Olivier Devuyst	1
8	Cardiovascular Risk and Renal Transplantation: Post Hoc Analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study 2005 ·American Journal of Kidney Diseases ·Alan G. Jardine, Bengt Fellström, John O. Logan, Edward Cole, Gudrun Nyberg, Carola Grönhagen‐Riska, Sören Madsen, Hans‐Hellmut Neumayer, Bart Maes, Patrice M. Ambühl, Anders Olsson, Terje Pedersen, Hallvard Holdaas	94
9	Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation 2005 ·Nephrology Dialysis Transplantation ·Hallvard Holdaas, Bengt Fellström, Alan G. Jardine, Gudrun Nyberg, Carola Grönhagen‐Riska, Sören Madsen, Hans‐Hellmut Neumayer, Edward Cole, Bart Maes, Patrice M. Ambühl, John O. Logan, Beatrix Staffler, Claudio Gimpelewicz	53
10	Influence of Everolimus on Steady‐State Pharmacokinetics of Cyclosporine in Maintenance Renal Transplant Patients 2005 ·The Journal of Clinical Pharmacology ·Klemens Budde, Gustav Lehne, Michael Winkler, Lutz Renders, A. E. Lison, Lutz Fritsche, Jean‐Paul Soulillou, Per Fauchald, Hans‐Hellmut Neumayer, (unknown), (unknown)	9
11	Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial 2004 ·Kidney International ·Bengt Fellström, Hallvard Holdaas, Alan G. Jardine, Ingar Holme, Gudrun Nyberg, Per Fauchald, Carola Grönhagen‐Riska, Sören Madsen, Hans‐Hellmut Neumayer, Edward Cole, Bart Maes, Patrice M. Ambühl, Anders Olsson, Anders Hartmann, John O. Logan, Terje R. Pedersen	91
12	D3 Immunosuppression - other (T688 - T710) 2003 ·Nephrology Dialysis Transplantation ·(unknown), Andreas Link, Matthias Girndt, Georg Nickenig, Michael Böhm, Hans Köhler, Johannes Waiser, (unknown), Klemens Budde, Hans‐Hellmut Neumayer	1
13	Old-for-Old Kidney Allocation Allows Successful Expansion of the Donor and Recipient Pool 2003 ·American Journal of Transplantation ·Lutz Fritsche, Jan Hörstrup, Klemens Budde, Petra Reinke, Markus Giessing, Stefan G. Tullius, Stefan A. Loening, P. Neuhaus, Hans‐Hellmut Neumayer, Ulrich Frei	99
14	The pharmacokinetics of pioglitazone in patients with impaired renal function 2003 ·British Journal of Clinical Pharmacology ·Klemens Budde, Hans‐Hellmut Neumayer, Lutz Fritsche, Władysław Sułowicz, Tomasz Stompór, (unknown)	111
15	Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial breakdown → 2003 ·The Lancet ·Hallvard Holdaas, Bengt Fellström, Alan G. Jardine, Ingar Holme, Gudrun Nyberg, Per Fauchald, Carola Grönhagen‐Riska, Sören Madsen, Hans‐Hellmut Neumayer, Edward Cole, Bart Maes, Patrice M. Ambühl, Anders Olsson, Anders Hartmann, D. Solbu, Terje R. Pedersen	660
16	The immunosuppressive potential of misoprostol—efficacy and variability 2003 ·Clinical Immunology ·Johannes Waiser, Torsten Böhler, (unknown), (unknown), Klemens Budde, Hans‐Hellmut Neumayer	5
17	Immunohistochemical double-staining of renal allograft tissue: critical assessment of three different protocols 2001 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Johannes Waiser, (unknown), Torsten Böhler, Birgit Rudolph, (unknown), Klemens Budde, Manfred Dietel, Hans‐Hellmut Neumayer	5
18	Pharmacodynamic Monitoring of Mycophenolate Mofetil 2000 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Klemens Budde, Petra Glander, Steffen Bauer, (unknown), Johannes Waiser, Lutz Fritsche, (unknown), Ivar Roots, Hans‐Hellmut Neumayer	56
19	Late conversion from steroids to azathioprine in cyclosporin-treated renal graft recipients 1989 ·Transplant International ·G. Offermann, (unknown), Donald J. Johann, Hans‐Hellmut Neumayer, (unknown), Anke Schwarz	7
20	Prostaglandin E<sub>2</sub> Promotes Hypotension on Low-Sodium Hemodialysis 1984 ·The Nephron journals/Nephron journals ·G. Schultze, (unknown), Hans‐Hellmut Neumayer, Karl Wagner, Frieder Keller, M. Molzahn, Santosh Nigam	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact